Pardanani, A
Tefferi, A
Article History
Received: 4 October 2014
Accepted: 10 October 2014
First Online: 12 December 2014
Competing interests
: AT was Principal Investigator for Phase-1/2 ruxolitinib study (NCT00509899) in myelofibrosis for the Mayo Clinic (Rochester) site. The sponsor (Incyte) funded the clinical trial and provided study drug, but was not involved in any way in the current manuscript. AP and AT are/have served as Principal Investigators for other clinical trials for myelofibrosis treatment with JAK inhibitors and other agents.